Top Midday Gainers

US equity futures were rising ahead of Friday's opening bell as traders continued to monitor the global tariff situation.

Dow Jones Industrial Average futures were up 0.6%, S&P 500 futures increased 0.7%, and Nasdaq futures were 0.8% higher.

China's Office of the Tariff Commission of the State Council said Friday it further raised import levies on US goods to 125% from 84% in response to President Donald Trump's "abnormally high" tariffs on Chinese goods.

Oil prices were little changed, with front-month global benchmarks up 0.1% at $63.38 per barrel and US West Texas Intermediate up 0.2% at $60.21 per barrel.

The US Producer Price Index, released at 8:30 am ET, fell by 0.4% in March following a 0.1% gain in February, compared with estimates compiled by Bloomberg for a 0.2% uptick.

Consumer sentiment, due at 10 am ET, is seen falling to 54.0 in the preliminary report for April from 57.0 in March.

In other world markets, Japan's Nikkei closed 3% lower, Hong Kong's Hang Seng ended 1.1% higher, and China's Shanghai Composite finished 0.5% higher. Meanwhile, the UK's FTSE 100 was up 0.9%, and Germany's DAX index was 1.3% lower in Europe's early afternoon session.

In equities, Stellantis stock was down 3% pre-bell after the company said it expects a 9% fall in Q1 shipments.

On the winning side, MSP Recovery shares were up 160% after the company said late Thursday it has agreed to a term sheet for several restructuring deals with Hazel Partners, Virage Capital Management and their affiliates.

MSP Recovery shares soared 128% pre-bell Friday after the company said late Thursday it has agreed to a term sheet for several restructuring deals with Hazel Partners, Virage Capital Management and their affiliates.

Upland Software shares increased 42% after Thursday's 3.5% loss.

BioNexus Gene Lab shares increased past 37% following a 2.3% drop in the previous session.

Design Therapeutics stock was up 6%, reversing from Thursday's losses.

MSP Recovery said late Thursday it has agreed to a term sheet for several restructuring transactions with Hazel Partners, Virage Capital Management and their affiliates.

MSP Recovery agreed to launch a restructuring and funding plan that includes several initiatives.

The initiatives are designed to reduce company costs, convert some debt into equity, release $1.2 billion of debt, and provide access to $9.8 million of bridge funding and up to $25 million of working capital, the company said.

The company has also obtained a payment extension and waiver from YA II PN allowing it to continue its core business.

The closing of the restructuring deal is expected no later than April 30, the company said.

Shares of MSP Recovery jumped more than 200% in after-hours activity Thursday.

By Connor Hart

Shares of MSP Recovery soared after the company agreed to a term sheet outlining several restructuring transactions with Hazel Partners and Virage Capital Management.

The stock doubled to $2.55 in after-hours trading. Through Thursday's close, shares have lost nearly 96% of their value in the past year.

The Medicare, Medicaid, commercial and secondary-payer reimbursement company said that initiatives included in the non-binding agreement will reduce costs, release $1.2 billion in debt and provide funding.

Under the agreement, Hazel would provide up to $25 million in operational funding through a structured facility, paid in monthly batches and subject to meeting certain milestones beginning in September, with a maturity date of June 30, 2027. The firm would additionally provide MSP with up to $9.8 million of bridge funding.

Virage would agree to waive all claims and release all liens against MSP relating to an outstanding loan in exchange for 43% equity interest.

"These transactions represent a critical turning point for MSP Recovery," Chief Executive Officer John Ruiz said. "By aligning with strategic partners and securing operational funding, we believe we have established a foundation that not only addresses past challenges but positions us for long-term growth.

Write to Connor Hart at connor.hart@wsj.com